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0022-2836 © 2006 Elsevier Ltd. Open acceThe extracellular matrix is a dynamic environment that constantly
undergoes remodelling and degradation during vital physiological
processes such as angiogenesis, wound healing, and development.
Unbalanced extracellular matrix breakdown is associated with many
diseases such as arthritis, cancer and fibrosis. Interstitial collagen is
degraded by matrix metalloproteinases with collagenolytic activity by
MMP-1, MMP-8 and MMP-13, collectively known as the collagenases.
Matrix metalloproteinase 1 (MMP-1) plays a pivotal role in degradation
of interstitial collagen types I, II, and III. Here, we report the crystal
structure of the active form of human MMP-1 at 2.67 Å resolution. This is
the first MMP-1 structure that is free of inhibitor and a water molecule
essential for peptide hydrolysis is observed coordinated with the active
site zinc. Comparing this structure with the human proMMP-1 shows
significant structural differences, mainly in the relative orientation of the
hemopexin domain, between the pro form and active form of the human
enzyme.© 2006 Elsevier Ltd. Open access under CC BY license.Keywords:matrix metalloproteinases; fibroblast collagenase; collagen; X-ray
crystallography; inhibitor-free*Corresponding authorIntroduction
Connective tissue remodeling is a complex pro-
cess involving a plethora of cytokines, growth
factors, and turnover of extracellular matrix (ECM).
The main enzymes that degrade ECM molecules are
matrix metalloproteinases (MMPs), which are also
known as matrixins. Under normal physiological
conditions, MMP activity can be regulated at
various stages: during transcription, proteolytic
processing of their inactive pro forms, zymogens,
as well as by inhibition of enzyme activity by
endogenous inhibitors such as tissue inhibitors of
metalloproteinases or TIMPs.1,2 These enzymes
have a similar domain structure: an N-terminal
signal sequence to target for secretion, a pro-peptide
domain to maintain latency, a catalytic domain
containing the catalytic zinc, a linker region, and a
C-terminal four-bladed propeller structure called
the hemopexin domain. Some of the MMPs have
additional domains, e.g. the fibronectin repeats in
gelatinases. These domains are important in subs-metalloproteinase;
ng author:
ss under CC BY license.trate recognition and in inhibitor binding.3 The
human MMP family to date comprises of about 23
enzymes that are classified based on their preferred
substrate and cellular localisation: collagenases,
gelatinases, stromelysins, elastase, membrane-type
MMPs and so forth.4
Collagenases (MMP-1, MMP-8 and MMP-13) are
the key enzymes that are capable of cleaving
interstitial fibrillar collagen. Apart from these
enzymes MMP-2 (gelatinase A) and MMP-14
(MT1-MMP) are also able to initiate the breakdown
of collagen fibrils.5,6 Interstitial collagens I, II and III
are triple-helical proteins that are the essential
structural components of all connective tissues
such as the cartilage, bone, skin, tendons and
ligaments. These extracellular glycoproteins provide
scaffolding of the tissue and play an important role
in cellular processes such as cell migration, prolif-
eration and differentiation. Physiological collageno-
lysis is integral to several biological processes such
as embryogenesis, tissue repair and remodeling,
angiogenesis, organ morphogenesis and wound
healing.7,9 The collagenases cleave the triple-helical
collagen approximately three-quarters away from
the N terminus of the substrate, resulting in three-
quarters and one quarter length fragments that are
unstable at body temperature and undergo dena-
turation, rendering them susceptible to other non-
specific tissue proteinases. However, under aberrant
Table 1. Crystallographic data processing and refinement
statistics
Space group Trigonal, P3221
Unit cell dimensions (Å) a=b=138.48, c=110.05
Resolution range (Å) 24.67–2.67
Total reflections measured 227,517
Unique reflections measured 30,817
Rsym (%)
a 8.0 (35.8)
I/σ(I) (outermost shell)b 22.6 (4.7)
Completeness (outermost shell) (%) 91.8 (91.2)
Rcryst (%)
c 22.3
Rfree (%)
d 25.9
A. Contents of the asymmetric unit
Protein atoms 5798
Solvent molecules 198
Ions 12 (4 zinc and 8 calcium)
B. r.m.s. deviation
Bond lengths (Å) 0.007
Bond angles (°) 1.35
C. Average B-factor (Å2)
All atoms (monomers A and B) 44.7 (A); 49.9 (B)
Main-chain atoms 44.4 (A); 50.0 (B)
Side-chain atoms 45.0 (A); 49.8 (B)
Ions (zinc and calcium) 44.9
Solvent molecules 34.1
Overall B-factor (Å2/Da)
(from Wilson plot)
63.1
a Rsym=∑hkl∑i|Ii(hkl−<I(hkl)>|/∑hkl∑iIi(hkl), where <I> is the
averaged intensity of the i observations of reflection hkl.
b Outermost shell: the resolution range of the outermost shell is
2.77–2.67 Å.
c Rcryst=∑|Fo|−|Fc|/∑|Fo|, where Fo and Fc are observed
and calculated structure factors, respectively.
d Rfree is equal to Rcryst for a random subset of reflections (2.2%)
not used in refinement.54
Figure 1. Ribbon representation of the three-dimen-
sional structure of human MMP-1 (E200A). Helices have
been coloured pink and the strands shown in green. There
are four calcium ions and two zinc ions found in the
structure that have been coloured grey and orange,
respectively. The secondary structural elements have been
annotated: helices (hA-hC), strands (s1–s5) of the catalytic
domain and blades (bI–bIV) of the hemopexin domain.
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pathological conditions such as cancer, atherosclero-
sis, arthritis, aneurysm and fibrosis.8,10
The proteolytic activity of the enzyme resides in
the catalytic domain but it requires the hemopexin
domain in order to cleave the three chains of the
triple-helical collagen.11 The crystal structure of por-
cine MMP-1,12 determined sometime ago, revealed
details of the active site structure and the specificity
pocket but this structure does not shed any light on
how collagenolytic MMPs can cleave the triple-
helical collagen. Recently, the X-ray structure of
human proMMP-1 (MMP-1 zymogen) was elu-
cidated.13 The structure revealed the interaction
between the pro-peptide and the hemopexin do-
main of the enzyme, which results in a “closed”
conformation of the zymogen in contrast to the
“open” conformation of catalytic domain of the
active MMP-1.
The three-dimensional structure of the human
MMP-1 (E200A), an active site mutant, reported
here takes us a step closer towards a more complete
understanding of the interaction of the collagenases
with the triple-helical collagens. It reveals new
features of the active protease and provides a
platform for understanding the structural changes
that accompany zymogen activation.Results
Overall structure
The structure of human MMP-1 (E200A) was
determined at 2.67 Å resolution with two monomers
(chains A and B) in the asymmetric unit of the
trigonal space group, P3221 (see Table 1 for crystal-
lographic statistics). The overall domain structure of
human MMP-1 is similar to that of the previously
solved full-length enzymes (Figure 1). The structure
comprises of the N-terminal catalytic domain, the
linker region and the C-terminal hemopexin
domain. The catalytic domain of one monomer
contacts the hemopexin domain of the other mono-
mer. Interestingly, the contact site used by the two
monomers in the asymmetric unit to form the dimer
is not the same as the dimerisation site observed in
the proMMP-1 structure13 or that for the MMP-9
hemopexin domain.14 This indicates that the dimer-
isation mechanism is perhaps not a general rule of
thumb for the hemopexin domains and is most
probably a crystallisation artefact. Monomers A and
B deviate from each other with an overall r.m.s.
deviation of 0.87 Å (for 367 Cα atoms). The dimer is
stabilised by eight hydrogen bonds and 54 van der
Table 2. van der Waals contacts at the dimer interface
Monomer A Monomer B No of contacts
Pro104 Gln333, Gly334(2) 3
Asp105 Gln333, Gly334(2), Gln335(4), Asn336(3) 10
Leu106 Gln333 2
Pro158 Val300(2), Phe301(2) 4
Glu180 Gln335 1
Asp181 Phe301, Gln335 2
Glu182 Gln335 4
Arg183 Pro303(2), Gln335(10), Asn336 13
Thr185 Asn336 1
Arg189 Gln304 5
Arg272 Pro104, Leu106(2), Pro107 4
Glu274 Pro104 1
Arg285 Pro104(2), Asp105 3
Val300 Arg183 2
Phe301 Asp105(4), Arg183 5
Gln335 Asp105(2), Leu106, Arg183(2), Thr185 6
Potential hydrogen bonds between monomers A and B at the dimer interface
Monomer A B-factor (Å2) Monomer B B-factor (Å2) Distance D… A (Å) Angle D–H… A (°)
Asp105 O 25.3 Asn336 Nδ2 23.2 2.9 144.2
Trp184 O 14.9 Asn336 Nδ2 22.1 2.9 167.2
Arg272 Nη1 34.9 Pro104 O 39.8 3.1 151.0
Arg285 Nη1 18.2 Asp105 Oδ1 18.4 3.3 166.3
Glu294 ε1 21.3 Arg146 Nη1 15.2 3.1 124.1
Val300 O 17.5 Arg183 Nη1 20.4 2.9 169.4
Gln335 Nε2 32.3 Asp105 O 18.8 3.3 168.9
Gln335 Nε2 22.6 Trp184 O 22.3 2.8 159.8
Hydrogen bond interactions were identified with the program HBPLUS31 The upper limit for the donor–acceptor distance was 3.3 Å,
except for contacts involving a sulphur atom (limit 3.6 Å); the lower limit for the donor–hydrogen–acceptor angle is 120°. Bond angles are
not given where the hydrogen position is ambiguous. Contact distances are the maximum allowed values of C–C, 4.1 Å; C–N, 3.8 Å; C–O,
3.7 Å; O–O, 3.3 Å; O–N, 3.4 Å; N–N, 3.4 Å; C–S, 4.1 Å; O–S, 3.7 Å; N–S, 3.8 Å. The contact distances were calculated using CONTACT.26
80 Crystal Structure of an Active Form of Human MMP-1Waals contacts (Table 2). These contacts are facili-
tated by a total of 33 residues (18 residues from
monomer A and 15 residues frommonomer B). Only
nine amino acid residues are common to both the
monomers: Pro104, Asp105, Leu106, Arg183,
Trp184, Thr185, Val300, Phe301 and Gln335. Apart
from the asymmetry seen in the residues that
participate from each monomer at the dimer inter-
face, we also observe a non-symmetric interaction
pattern. However, it is believed that this dimer is not
physiologically relevant, as we found that human
MMP-1 is a monomer in solution (R.V. & H. N.,
unpublished results).
Catalytic domain
The structure of MMP-1 catalytic domain is very
similar to those of other MMPs. The metalloprotei-
nase domain is about 160 amino acid residues in
length with the catalytic zinc ion residing in the C-
terminal segment of this domain. The catalytic
fragment of the protease consists of three α-helices
and a highly twisted five-stranded β-sheet. The
active site zinc is bound in the sequence
HELGHXXGXXH by the three His residues:
His199, His203, His209 and a water molecule at
the active site cleft (Figure 2). This is the first MMP-1
structure where a water molecule essential for
peptide hydrolysis is observed at the active site
because all the previous structures of the metallo-proteinase domain of MMP-1 are in the inhibited
state of the enzyme.
Also observed in this domain is the salt bridge
between the ammonium group of the N-terminal,
Phe81 and the carboxylate group of the side-chain of
Asp232. The generation of the correct N terminus
(Phe81) in the activation process of proMMP-1 is
crucial for the enzyme to have full activity against
collagen.15 If the N terminus is either longer or
shorter the activity against collagen drops to 30–
40%.15 Only with the correct N terminus the
formation of the salt bridge is possible, and this
stabilises the structure of the N terminus as was
originally shown for MMP-8.16,17
Alignment of the pro-enzyme (1SU3) structure
with that of the mature enzyme (2CLT here) shows
Phe81 to have moved some 17 Å from its original
position in the zymogen form of collagenase-1
(Figure 3(a)). The structure of proMMP-3 (PDB
code: 1SLM)18 was aligned as well to help
calculate the displacement of Phe81. The first
seven N-terminal residues were not observed in
the proMMP-1 structure because of lack of proper
visible electron density.13 This deviation gradually
decreases and by residue Pro88 the two structures
are in register and remain remarkably similar
throughout the catalytic domain. There are only
slight differences, if any, in the side-chain orienta-
tion of the N-terminal residues in the catalytic
domain cleft (Figure 3(b)).
Figure 2. Structure of the active site of the E200Avariant of humanMMP-1 superimposed with the wild-type enzyme
(PDB code: 1CGL).20 The mutant enzyme is in pink and the wild-type enzyme in grey. The water molecule at the catalytic
site that is important for peptide bond hydrolysis is shown in cyan and the catalytic zinc is displayed in orange. Electron
density (2Fo-Fc map contoured at 1.0σ) is shown around the catalytic site residues, the catalytic zinc and the water
molecule.
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tion facilitated by residues His149, Asp151, His164
and His177. The catalytic domain of MMP-1 also
contains three calcium-binding sites. Either four or
five liganding residues coordinate all the calcium
ions, except one in the catalytic domain of mono-
mer A (Table 3). One calcium ion packs the S-loop
(between strands s3 and s4) against the liganding
residues from strand s5. The second calcium ion of
the catalytic domain is sandwiched between strand
s3 and the loop containing strands s4 and s5. TheFigure 3. Stereo view of the comparison of procollagenase-
procollagenase-1 (green; PDB code: 1SU3) and prostromelysi
highlight the major movement of Phe81 (N-terminal residue
activation. Also shown is the resulting salt-bridge between Phe
trajectory the N-terminal segment (81–87) would take in th
superimposed to help visualise this movement as this segmen
up of the N-terminal area (the area boxed in (a). Colour codinthird calcium site is determined by the presence of
the critical residue, Asp105 that comes from the
loop following strand s1. The other residues
(Glu180 and Glu182) that provide coordination to
this calcium ion come from the loop following
strand s5. One interesting feature observed in this
crystal structure by virtue of dimerisation is that
residue Gln335 from monomer B contributes the
fourth coordinating ligand for this calcium ion.
This feature, however, is not replicated in the
corresponding calcium-binding site in monomer B.1 with the active enzyme. (a) Active humanMMP-1 (pink),
n-1 (grey; PDB code: 1SLM) have been superimposed to
of active enzyme; Phe83 in active stromelysin-1) upon
81 and Asp232. The dotted green line represents the likely
e procollagenase-1. The prostromelysin-1 structure was
t in the procollagenase-1 structure is disordered. (b) Close-
g for the structures is the same as that followed for (a).
82 Crystal Structure of an Active Form of Human MMP-1Details of the metal site geometries can be found in
Table 3.
Linker region
In MMPs the catalytic domain is followed by a
stretch of 15–65 amino acid residues referred to as the
linker or the hinge region. This region is rich in
proline residues and replacement of those with
alanine drastically reduced the collagenolytic activ-
ity of MMP-8 (neutrophil collagenase),19 indicating
that the presence of the correct linker structure is
important for collagenolysis. This region in MMP-1
with 16 residues is well defined in the present
structure unlike that in the full-length crystal
structure of porcine collagenase. The conformation
of the linker region is quite similar in both proMMP-
113 and the present MMP-1 structures (Figure 4(a)).
The residues of the linker region make extensive
contacts (six hydrogen bonds and 73 van der Waals
contacts; Table 4) with both the catalytic and the
hemopexin domain of the enzyme. These interac-
tions stabilise the domain arrangement in MMP-1,
which is required for the concerted action of the two
domains. Comparing the interactions of the linker
region with the catalytic and the hemopexin domain
in both the pro-enzyme and the active enzyme did
not reveal many differences. Most of the interactions
seen in proMMP-1 (seven hydrogen bonds and 71
van der Waals contacts) are still observed in the
present structure, indicating that the activation of
the enzyme does not result in structural changes and
the overall structure of the areas around the linkerTable 3. Metal site geometries (distance in Å)
Metal site
Coordinating
residue Monomer A Monomer B
Catalytic Zinc His199 NE2 2.19 2.19
His203 NE2 2.13 2.23
His209 NE2 2.20 1.99
Water 2.32 2.31
Structural Zinc His149 NE2 2.15 2.32
Asp151 OD2 2.08 2.22
His164 NE2 2.21 2.17
His177 ND1 2.09 2.12
Calcium 1 Asp105 OD2 2.40 2.43
Glu180 O 2.27 2.35
Glu182 O 2.40 2.39
Gln335 OE1 (B) 2.28 –
Glu180 OE2 – 2.14
Calcium 2 Asp139 O 2.42 2.29
Gly171 O 2.29 2.25
Gly173 O 2.05 2.11
Asp175 OD2 2.30 –
Water 2.42 2.30
Calcium 3 Asp156OD2 2.26 2.44
Gly157 O 2.42 –
Gly159 O 2.03 2.29
Asn161 O – 2.40
Asp179 OD2 2.39 2.35
Glu182 OE2 2.43 2.23
Calcium 4 Asp266 O 2.36 2.31
Glu310 O 2.34 2.41
Asp359 O 2.48 2.37
Asp408 O 2.67 2.45region are mostly conserved. Interestingly though,
the hydrogen-bonding interactions (Table 4) within
this region are quite different between the two forms
of the molecule. There are a total of seven hydrogen
bonds within the linker region of active MMP-1
(Figure 4(b)) compared to the five observed in
proMMP-1 (Figure 4(c)), with only two bonds
common to both structures This difference in the
number of hydrogen bonds is perhaps not of much
significance when seen in the light of the extensive
contacts this region makes with the other two
domains.
Hemopexin-like domain
The hemopexin domain starts with Cys259 and
forms a complete circle by joining to Cys447 in a
disulphide bond that connects blade bI with blade
bIV, giving this domain the characteristic four-
bladed β-propeller structure. Each blade starts
near the periphery with either the motif DAA or
DAX, in which the Asp residues (Asp266, Asp359
and Asp408) coordinate the central calcium ion
through their carbonyl oxygen atom. Glu310 pro-
vides the fourth coordination thus completing the
acidic patch at the entrance of the central, solvent-
accessible channel (Table 3). The side-chains of these
residues form salt bridges to the neighbouring β-
strands holding the entrance of the central channel
together. Three water molecules are found trapped
in the centre of this channel. These, however, are not
involved in the coordination geometry of the
calcium ion at the tunnel centre. Two of the water
molecules are at positions corresponding to the
sodium and chloride ion in the proMMP-1
structure.12 The water molecule corresponding to
the sodium ion is at hydrogen-bonding distances to
the carbonyl oxygen atom of Ile268, Ala312, Ala361
and Val410. The same cannot be said for the one
corresponding to the chloride ion, which does not
make any hydrogen bonds with the main-chain
amides of the residues mentioned above. It is very
likely that the presence of these ions is a conse-
quence of the crystallisation conditions rather than
a stability requirement for the hemopexin-like
domain.
Comparison with the porcine MMP-1 and the
human proMMP-1 structures
Full-length human MMP-1, human proMMP-113
and porcine MMP-112 were superimposed on the
basis of the catalytic domain of the three structures.
Alignments were also done for just the hemopexin
domain of the molecules. As expected both types of
alignments gave the same outcome whereby the
active form of the enzyme (human and porcine)
were closer in their structure as opposed to the
proMMP-1 structure. The average r.m.s. deviation
over 367 Cα atoms of the porcine and human
MMP-1 is ∼1.4 Å, whereas the r.m.s. deviation
when aligning the full-length active MMP-1 with
the proMMP-1 structure is 1.6 Å. If, however, we
Figure 4. Comparison of the hydrogen-bonding interactions within the linker region. (a) Superposition of active
MMP-1 (pink) and procollagenase-1 (green) to highlight the conformational similarity of the linker region in the two
structures. (b) Stereo view of the linker region in active MMP-1 showing the hydrogen-bonding interactions between the
residues. (c) Stereo view of the linker region in procollagenase-1 showing the hydrogen bonds within the region.
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eration, then the conformational differences that lie
within this domain are brought to light (Figure 5(a)).
The superimposed porcine and human MMP-1 he-
mopexin-like domains vary by 1.2 Å (maximumdisplacement of 5.2 Å). This value increases to 1.7 Å
when superimposing the hemopexin-like domains
of the active human MMP-1 and the human
proMMP-1. A considerable change in conformation
is reflected in the residues that interact with the pro-
Table 4. Linker region interactions in human MMP-1 and proMMP-1
van der Waals interactions
Residue MMP-1 interactions proMMP-1 interactions
Gly242 Pro127, Gln238(8), Tyr241 Thr126(2), Pro127(2), Gln238(7),
Ile240, Tyr241
Arg243 Pro127, Gln238(6) Thr126, Pro127, Gln238(2)
Ser244 Asn124, Val125(5) Asn124, Val125(2), Thr126(3)
Gln245 Pro127 –
Pro250 Asn124 Asn124, Val125(2)
Ile251 Gln231, Ile234(2) Ile234
Gly252 Leu229, Gln231(7), Ile234(2) Leu229, Gln231, Ile234(2)
Pro253 Leu229, Ala230, Arg281(2) Gln228(5), Leu229, Ala230(2), Arg281(4)
Gln254 Gln231(2) Gln231(2)
Thr255 Asp212(2), Ile213, Gly214, Leu295 Asp212(4), Gly214, Phe282, Leu295
Pro256 Leu263, Lys279, Phe282(5), Met284(2) Phe282(3), Met284
Lys257 Cys259 Cys259, Asp260(3)
Ala258 Lys257, Cys259(3), Asp260, Asn442, Phe445(6), Cys447(2) Cys259(3), Asp260, Leu263, Val2932), Asn442(2), Phe445(2), Cys447
Hydrogen bonding interactions with the linker region
Source Target Distance (Å)
Gly242 N Gln238 O 2.66
Gln249 OE1 Gln238 NE2 2.96
Gly252 N Gln231 OE1 3.09
Pro253 O Gln231 N 2.98
Thr255 OG1 Asp212 OD1 2.64
Lys257 O Asp60 N 3.14
Lys257 O Cys259 N 3.18
Ala258 O Asn442 ND2 3.02
Hydrogen bonding interactions within the linker region
Source Target
Arg243 O Glu245 N
Ser244 N Gln249 OE1
Ser244 O Gln249 NE2
Ser244 OG Asn246 N
Glu245 O Pro247 N
Asn246 O Glu249 N
Glu249 O Pro251 N
Gly252 O Glu254 N
Gln254 O Pro256 N
Thr255 O Lys257 N
Interactions in bold font are common to both the active MMP-1 and the pro-enzyme; interactions in bold and italics are unique to the pro-
enzyme; the rest are unique to the active MMP-1.
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the Phe289-Tyr290-Pro291 region of the hemopexin-
like domain. Table 5 shows these residues, their
interactions and the shift in Cα position observed
when the pro and active forms of human MMP-1
were superimposed. The largest movement of 16 Å
is observed for the residue, Phe289 (Figure 5(b)).
Such a perturbation in structural conformation is
not evident in the catalytic domain of the enzyme
(Table 5). It seems like Arg281 acts as a pivot
around which the hemopexin-like domain under-
goes displacement upon activation as suggested by
Jozic et al.13
One region in the catalytic domain that generates
interest is the region between Tyr218 and Tyr221.
The shift in the Cα position between the active and
the proMMP-1 is not as dramatic as that observed
for the Phe289-Tyr290-Pro291 region but they are
involved in several interactions with the pro domain
around the cysteine-switch region. As a result when
the pro-enzyme undergoes activation, this region ofthe catalytic domain opens wider and further
exposes the crucial cis-configured Glu190-Tyr191
peptide in MMP-1.Discussion
Reconciliation of structural findings:
pro-collagenase versus active collagenase
MMPs are multi-domain enzymes that consist of a
pro domain, catalytic domain, a linker region and a
hemopexin-like domain. Cleavage of the pro
domain leads to a substantial rearrangement of the
N-terminal residues 81–88 (Figure 3(a)). The activa-
tion process swings Phe81 towards the proteinase
domain and terminates with a salt link between the
amine of Phe81 and the carboxylate side-chain of
Asp232. This interaction imparts several-fold
greater enzymatic activity to MMP-1 than those
Figure 5. Conformational dif-
ferences in the hemopexin-like
domain of proMMP-1 and active
MMP-1. (a) Shown in pink is
human active MMP-1, in grey is
porcine MMP-1 and green is for
human proMMP-1. Superposition
was based on the catalytic domain
of all the three molecules. The
stereo view highlights the relative
movement of the hemopexin-like
domain of proMMP-1 and active
MMP-1. Activation of the pro-
enzyme (green: closed configura-
tion) results in an open-conforma-
tion (pink/grey: active MMP-1). (b)
Major displacement of the Phe289-
Tyr290-Pro291 loop of the hemo-
pexin-like domain in the pro and
active form of the human enzyme.
Both forms of the enzyme have
been coloured grey except for the
displaced loop, which is shown in
pink in the active enzyme and in
green in the pro-enzyme. All the
Pigures were made using the pro-
gram MOLSCRIPT.30
85Crystal Structure of an Active Form of Human MMP-1with either an extended or a shorter N terminus,
which lack the salt linkage.17
Previously an inhibitor-free structure of the cataly-
tic domain of MMP-1 was reported.20 This structure
was, however, unique in the sense that theN-terminal
Leu-Thr-Glu-Gly (83–86) residues of one molecule
occupied the active site of the other molecule thus
forming an unnatural inhibited complex, which
should not really be considered as an inhibitor-free
structure. The present structure on the other hand
stands unique in being elucidated in the absence of
an inhibitor. This is the first unliganded structure of
the full-length MMP-1 where a water molecule is
seen at the active site providing the fourth ligand for
the catalytic zinc in the tetrahedral coordination
sphere (Figure 2). It must be mentioned here that the
present structure is an active site mutant where the
catalytic glutamate residue has been mutated to analanine. It is likely that the scissile peptide bond and
the catalytic glutamate (Glu200) flank the active site
water molecule on either side. The favourable
hydrogen bond between Glu200 and the water mo-
lecule would make it more nucleophilic. The
strongly polarised carbonyl group of the scissile
bond (by virtue of its interaction with the catalytic
zinc) would face a properly oriented water molecule.
An unstable transition state results in the transfer of
one water proton to the leaving nitrogen (the amino
group of the scissile bond) via the Glu200 carbox-
ylate shuttle. This is followed by the cleavage of the
peptide bond and concomitant shuttle of another
water proton to the amino group. This hypothesis
will, however, need to be substantiated with a
transition state structure.
The linker region is considered to play an
important role in collagenolysis,19,21 but its exact
Table 5. Effects of interaction with pro domain residues
Pro domain residues
Shift in Cα
position (Å)MMP-1 residues van der Waals interactions Hydrogen bonds
Gly160 Pro71(2), Arg72 Gly160 O–Arg72 N (2.9 Å) 0.87
Asn161 Arg72(2), Gly74(4) Asn161 ND2–Gly74 N (3.0 Å) 0.33
Leu162 Pro71(2) Leu162 N–Arg72 O (2.9 Å) 0.33
Asn163 Cys73(2), Gly74 Asn163 O–Gly74 N (2.8 Å) 0.09
His164 Val75 – 0.00
Ala165 Val75(2) – 0.17
Tyr191 Pro71(6) – 0.00
His199 Cys73(4) – 0.36
His203 Cys73(2), Val75(3) – 0.50
His209 Phe51, Cys73(4), Val75(4), Pro76, Asp77 His209 ND1–Asp77 OD1 (2.7 Å) 0.44
Ser210 Phe51(4) – 0.50
Thr211 Phe51(11) – 0.79
Tyr218 Phe52(4) – 0.85
Pro219 Phe51(3), Phe52(2), Arg72(6), Asp77(3) Pro219 O–Cys73 N (2.9 Å) 1.08
Ser220 Gln70(2), Pro71, Arg72(2), – 1.18
Tyr221 Pro71 Tyr221 N–Pro71 O (3.0 Å) 1.27
Phe289 Lys55, Asp61, Glu63(4) – 15.52
Tyr290 Gly53(2), Leu54(2), Glu63(5) Tyr290 OH–Glu63 OE1 (2.6 Å) 11.88
Pro291 Gly53, Leu54, Lys55(4) – 8.87
86 Crystal Structure of an Active Form of Human MMP-1role is not clear. The structures of both proMMP-1
and active MMP-1 have revealed the residues of
this region to be in close contact with the catalytic
and the hemopexin-like domain. Comparative
analysis of the extensively similar contacts made
by the residues of the hinge region reveal that
despite being highly exposed with no secondary
structure, the conformation of the linker peptide is
perhaps a signature of its sequence and does not
depend on the crystal packing (Figure 4(a)).
Mutagenesis studies of this region result in
decreased collagenolytic activity of MMP-121 and
MMP-8.19 This may be due to structural changes in
this region affecting the interactions with the
catalytic and hemopexin domains that are required
for collagenolysis.22
The cleavage of the pro domain to form the active
enzyme is accompanied by major conformational
rearrangement in the residues that interact with the
pro domain. Residues from both the catalytic domain
and the hemopexin-like domain make interactions
with the pro domain residues. The effects on the
overall backbone structure of the catalytic domain is
minimal; the effects on the hemopexin-like domain is,
however, quite dramatic (Figure 5(a)). The Phe289-
Tyr290-Pro291 region of the hemopexin-like domain
undergoes the most significant conformational
change (Figure 5(b)). In essence, the hemopexin-like
domain undergoes a major displacement towards the
catalytic domain, thus widening the cleft between the
proteinase domain and the hemopexin-like domain
on the active site face of the enzyme. This altered
configuration makes the active site residues and the
RWTNNFREY (residues 183–191) interface, a seg-
ment critical for collagenolysis,23 more accessible for
native collagen.
Implications for collagenolysis
Despite growing awareness of the importance of
collagen-recognising determinants it is still unclearas to which part of the collagenase molecule makes
the first contact with the triple-helical collagen.
Several hypotheses have been suggested to try and
explain the steps involved in collagenolysis (themost
recent by Jozic et al.13). Docking studies were
performed using a single-stranded, collagen α1(I)-
like 15mer peptide with the Gly-Ile cleavage site
incorporated in an attempt to better understand the
functioning of the active enzyme. The peptide was
modelled on the known structure of one of the chains
of the triple-helical collagen (PDB code: 1BKV).24
Several solutions were generated. We used localised
interactions as our guide to help us pick one possible
solution: (a) contact of the carbonyl group of the Gly-
Ile bond of the peptide with the active site
determinants, especially the catalytic zinc; and (b)
contact with the critical cis-configured Glu190-
Tyr191 peptide. This solution revealed the peptide
to be aligned to the continuous bulge-edge strand
(Gly160-Phe166) and the wall-forming segment
(Pro219-Phe223) in an extended manner. This solu-
tion, however, upon energy minimisation moved
outside of the coordination sphere of the catalytic
zinc but it was still close enough to be polarised by
the catalytic zinc. Since the peptide was only 15
amino acid residues long, we could not see any
interactions with the C-terminal hemopexin-like
domain. It has been proposed that the triple-helical
collagen would run via the Glu190-Tyr191 cis-
peptide exosite making extensive interactions with
the residues of the hemopexin-like domain.22
The structure of the active form of human MMP-
1 has provided us insights on the conformational
changes that occur upon activation of the pro-
enzyme and these are valuable clues towards
understanding the mechanism of collagenolysis. A
better understanding of the mechanism of collagen
cleavage will assist towards design of inhibitors
that would specifically interfere with collagenolysis
without affecting (beneficial) the cleavage of other
substrates.
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Cloning, protein expression and protein
purification
The catalytically inactive mutant proMMP-1 (E200A)
was cloned, overproduced, refolded, and purified as
described.22 A catalytic site mutant of this enzyme was
chosen in order to prevent autocatalytic cleavage during
crystallisation. The mutant zymogen was activated as
described22 at a final concentration of 554 μM in the
presence of 1:80 molar ratio of MMP-3 lacking the
hemopexin-like domain (MMP-3ΔC) and 1 mM 4-amino-
phenylmercuric acetate for 90 min at 37 °C. The activation
mixture was directly applied to a Sephadex S-200 gel
filtration column (diameter 26 mm, length 900 mm) in
50 mM Tris–HCl (pH 7.5), 150 mM NaCl, 10 mM CaCl2,
0.02% (w/v) sodium azide, to separate the “active” form
of MMP-1 (E200A) from MMP-3ΔC, 4-aminophenylmer-
curic acetate, and remnants of the pro-peptide. Fractions
containing MMP-1 (E200A) were pooled and concentrated
using a Vivacell 250 ml with a 5 kDa cutoff membrane,
followed by a Vivaspin 20 with a 5 kDa membrane
(Vivascience). The protein was stored at room temperature
as incubation at 4 °C resulted in precipitation.Crystallisation, data collection and processing
MMP-1 (E200A) was crystallised using the hanging
drop vapour-diffusion method. The protein (2 μl at a
concentration of 21 mg/ml) was mixed with 2 μl of the
reservoir solution containing 0.1 M Tris (pH 7.5), 1.5 M
ammonium formate and 10% (w/v) polyethylene glycol
(PEG) 8000. Crystals appeared and grew to their
maximum size within two weeks at 16 °C. A cryoprotec-
tant solution prepared by supplementing the reservoir
with 25% (v/v) glycerol enabled the crystals to be flash-
frozen in liquid nitrogen.
Flash-cooled MMP-1 (E200A) crystals were used to
collect diffraction data to a resolution of 2.67 Å on PX 14.1
at the Synchrotron Radiation Source, Daresbury (UK). The
data were processed and scaled using HKL2000.25 The
crystals belong to the space group P3221, with cell
dimensions of a=b=138.48 Å and c=110.05 Å. There are
two monomers in the asymmetric unit with solvent
content of about 60%. Data reduction using the program
TRUNCATE26 estimated an overall B-factor of 63.1 Å2/Da
from the Wilson plot. Details of the data processing
statistics are presented in Table 1.
Structure determination
The solution for the MMP-1 (E200A) structure was
found using the program PHASER.26 Human proMMP-1
(PDB code: 1SU3)13 was used as the search model with the
pro-peptide domain removed from the structure. Log-
likelihood gain (LLG) of 161 for the first solution increased
to an LLG value of 1091 when the second monomer in the
asymmetric unit was located indicating the solutions were
indeed the right ones.
Refinement
Crystallographic refinement was carried out using
the program CNS27 at 2.67 Å resolution against 85.1% ofthe measured data. A test set of random reflections of 2.2%
was excluded from the full data set for cross-validation
purposes by calculating the free R-factor (Rfree) to monitor
refinement trend.28 Initial round of refinement with the
twomonomers found by PHASER26 resulted in anRcryst of
45.1% and an Rfree of 50.6%. Once the six N-terminal
residues in both the monomers were built in and all the
ions (two zinc ions and four calcium ions per monomer)
were added and the model subjected to simulated
annealing, the Rcryst and the Rfree dropped to 31% and
38%, respectively. Iterative cycles of refinement (energy
minimisation, simulated annealing and individual tem-
perature factor (B-factor) refinement) using CNS27 and
model building with reference to 2Fo-Fc and Fo-Fc maps
using the program Coot29 progressively improved the
phases. In the final stages of refinement, water molecules
with peaks greater than 3σ in the Fo-Fc maps and those
within hydrogen bonding distances from appropriate
atoms were incorporated into the structure.
The final refined structure at 2.67 Å resolution has an
Rcryst of 22.3% and an Rfree of ∼26%. Both monomers,
chains A and B have the full complement of the amino
acids: from Phe81 to Cys447. Residues 117, 356, 369, 385,
386 and 424 of chain A and residues 257, 272, 287, 424 and
446 of chain B have been modelled as alanine residues
because of the lack of visible electron density beyond Cβ
atom. Analysis of the Ramachandran plot using the
program PROCHECK26 indicated that ∼81% of the
residues are in the most favourable region of the ϕ-φ
plot and about 17% lie in the additional allowed region.
The structure also consists of 198 water molecules. Details
of the refinement statistics are given in Table 1.
Protein Data Bank accession codes
The atomic coordinates and the structure factors of the
human MMP-1 (E200A) have been deposited with the
RCSB Protein Data Bank (accession codes 2CLT and
R2CLTSF, respectively).
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